© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
BioAge Labs Inc. (BIOA) stock surged +0.95%, trading at $9.59 on NASDAQ, up from the previous close of $9.50. The stock opened at $9.39, fluctuating between $9.39 and $9.76 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 04, 2026 | 9.39 | 9.76 | 9.39 | 9.59 | 313.41K |
| Sep 03, 2026 | 9.90 | 9.98 | 9.41 | 9.50 | 407.26K |
| Sep 02, 2026 | 9.59 | 10.05 | 9.43 | 9.73 | 541.25K |
| Sep 01, 2026 | 9.28 | 9.72 | 9.15 | 9.52 | 604.99K |
| Aug 31, 2026 | 9.61 | 9.63 | 9.20 | 9.50 | 1.03M |
| Aug 28, 2026 | 10.06 | 10.25 | 9.60 | 9.65 | 451.76K |
| Aug 27, 2026 | 9.93 | 10.23 | 9.80 | 10.08 | 475.27K |
| Aug 26, 2026 | 10.03 | 10.03 | 9.76 | 9.84 | 503.86K |
| Aug 25, 2026 | 9.55 | 10.13 | 9.55 | 10.11 | 498.25K |
| Aug 24, 2026 | 9.57 | 9.65 | 9.16 | 9.38 | 658.87K |
| Aug 21, 2026 | 9.78 | 9.92 | 9.48 | 9.48 | 453.19K |
| Aug 20, 2026 | 10.64 | 10.73 | 9.63 | 9.69 | 776.76K |
| Aug 19, 2026 | 10.69 | 10.88 | 10.38 | 10.75 | 411.17K |
| Aug 18, 2026 | 10.31 | 10.75 | 10.19 | 10.46 | 478.46K |
| Aug 17, 2026 | 10.60 | 10.71 | 10.15 | 10.40 | 671.63K |
| Aug 14, 2026 | 10.37 | 10.63 | 10.10 | 10.60 | 444.34K |
| Aug 13, 2026 | 10.62 | 10.86 | 10.37 | 10.43 | 536.08K |
| Aug 12, 2026 | 10.78 | 10.95 | 10.43 | 10.48 | 614.54K |
| Aug 11, 2026 | 11.49 | 11.55 | 10.44 | 10.67 | 761.04K |
| Aug 10, 2026 | 11.70 | 11.89 | 11.25 | 11.45 | 592.29K |
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
| Employees | 61 |
| Beta | 0.93 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |